Definium Therapeutics Inc (DFTX) 13F Filings: Institutional Buyers & Sellers (Q2 2026)

DFTX ranks #1673 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

DFTX is a top-conviction position for Octagon Capital Advisors LP — at 12.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in DFTX belongs to BlackRock, Inc., but the position matters far more to Octagon Capital Advisors LP, who has 12.5% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Driehaus Capital Management LLC has added to its DFTX position for two straight quarters, increasing it by $234.5M to reach $322.0M today.

DFTX is up 1% today, and institutions have been net buyers of $2.2B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

DFTX reported a net loss of $183.8M in its latest fiscal year.

• Not yet profitable — net loss of $183.8M in the latest fiscal year
• Net income declined year over year, from -$108.7M to -$183.8M
• Operating cash flow was negative, using $131.6M in cash
• Current ratio of 6.29x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.32x equity — within a conventional range